Rutgers Robert Wood Johnson Medical School

Summary

Rutgers Robert Wood Johnson Medical School is a medical facility located in New Brunswick, New Jersey. This center is recognized for care of Cystic Fibrosis, Heart Failure, Cancer, Multiple Sclerosis, Childhood Leukemia and other specialties. Rutgers Robert Wood Johnson Medical School is involved with conducting 123 clinical trials across 486 conditions. There are 30 research doctors associated with this hospital, such as Sabine s Coppieters, MD, Howard S. Hochster, Mridula George, MD, and Mark Russo, MD.

Top PIs

Clinical Trials running at Rutgers Robert Wood Johnson Medical School

Colon Cancer

Diabetes

Asthma

Cystic Fibrosis

Von Willebrand Disease

Heart Disease

Acute Lung Injury

Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome

Alzheimer's Disease

High Dietary Fiber Formula

for Colon Cancer

This phase II trial tests whether NBT-NM108 works in reducing chemotherapy-induced diarrhea in patients with colon cancer that has spread to other places in the body (metastatic). Irinotecan is one of the most used medicine for colon cancer, but it leads to diarrhea in most patients receiving it and among some of them, severe diarrhea can occur. NBT-NM108 is a high dietary fiber formula that is developed based on research findings that have shown that high fiber diets can help maintain healthy bacteria in the gut and improve gut function. Giving NBT-NM108 to patients with colon cancer receiving chemotherapy may help relieve or lessen diarrhea symptoms and lead to improved tolerance of the chemotherapy drug, irinotecan.

Recruiting

1 award

Phase 2

2 criteria

Chemotherapy + Bevacizumab

for Metastatic Colorectal Cancer

This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)

Recruiting

1 award

Phase 2